Company intelligence / Profile preview

Guangdong Ruishun Biotechnology Co., Ltd.

Zhongshan, Guangdong Sheng, Chinaruigubiotech.com ↗

Ownership: Private
Development stage: Other

Overview

The company has several programs in clinical trials, with RC-1012 in Phase 1/2 for Acute Myeloid Leukemia, CD19-CAR-DNT Cells in Phase 1 for B-cell lymphoma, and RS-001 in Phase 1 for High grade B-cell lymphoma. RJMty-19 is in Phase 1 for SLE.

Therapeutic areas: OncologyImmunology
Modalities: CAR-T cellsUniversal CAR-TCAR-DNT cells
Industry: Biotech

Drug pipeline

5 assets

RC1012

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Guangdong Ruishun Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangdong Ruishun Biotechnology Co., Ltd..

Explore the full profile